Atara Biotherapeutics (NASDAQ:ATRA) CAO Sells $23,794.76 in Stock

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) CAO Yanina Grant-Huerta sold 1,804 shares of the business’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $13.19, for a total transaction of $23,794.76. Following the transaction, the chief accounting officer directly owned 33,454 shares in the company, valued at $441,258.26. The trade was a 5.12% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Yanina Grant-Huerta also recently made the following trade(s):

• On Monday, November 17th, Yanina Grant-Huerta sold 1,804 shares of Atara Biotherapeutics stock. The stock was sold at an average price of $13.19, for a total transaction of $23,794.76.

Atara Biotherapeutics Stock Up 2.1%

Shares of NASDAQ:ATRA traded up $0.28 during trading on Wednesday, reaching $13.74. 39,536 shares of the company traded hands, compared to its average volume of 96,447. The firm has a fifty day simple moving average of $13.70 and a 200 day simple moving average of $11.05. Atara Biotherapeutics, Inc. has a 1-year low of $5.01 and a 1-year high of $18.70. The firm has a market cap of $99.07 million, a P/E ratio of 6.30 and a beta of 0.26.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its quarterly earnings results on Wednesday, November 12th. The biotechnology company reported ($0.32) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.83) by $0.51. Atara Biotherapeutics had a net margin of 15.40% and a negative return on equity of 41.78%. The business had revenue of $3.45 million for the quarter, compared to the consensus estimate of $2.74 million. As a group, research analysts anticipate that Atara Biotherapeutics, Inc. will post -10.39 EPS for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

A number of large investors have recently bought and sold shares of ATRA. EcoR1 Capital LLC raised its holdings in Atara Biotherapeutics by 7.7% during the first quarter. EcoR1 Capital LLC now owns 573,183 shares of the biotechnology company’s stock valued at $3,405,000 after buying an additional 41,049 shares in the last quarter. Staley Capital Advisers Inc. boosted its stake in shares of Atara Biotherapeutics by 60.0% during the 1st quarter. Staley Capital Advisers Inc. now owns 80,000 shares of the biotechnology company’s stock worth $475,000 after acquiring an additional 30,000 shares in the last quarter. Mackenzie Financial Corp increased its holdings in shares of Atara Biotherapeutics by 183.5% during the 3rd quarter. Mackenzie Financial Corp now owns 63,816 shares of the biotechnology company’s stock valued at $914,000 after acquiring an additional 41,302 shares during the last quarter. Vanguard Group Inc. increased its holdings in shares of Atara Biotherapeutics by 6.6% during the 3rd quarter. Vanguard Group Inc. now owns 203,438 shares of the biotechnology company’s stock valued at $2,915,000 after acquiring an additional 12,677 shares during the last quarter. Finally, GSA Capital Partners LLP raised its stake in shares of Atara Biotherapeutics by 33.8% in the 3rd quarter. GSA Capital Partners LLP now owns 26,213 shares of the biotechnology company’s stock valued at $376,000 after acquiring an additional 6,622 shares in the last quarter. 70.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Atara Biotherapeutics in a research note on Thursday, November 13th. One equities research analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $21.00.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.